Description
Denik Pharm BETA TRUTIDE (RETATRUTIDE) is a cutting-edge, investigational triple hormone receptor agonist developed to address obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Unlike previous incretin-based therapies, it targets three critical pathways in metabolic regulation:
| Contents |
BETA TRUTIDE
- RETATRUTIDE 5mg Vials (for SC or IM Administration) x 5
- Ampoule: 2ml Sterile Water for Injection x 5
|
| Description |
BETA TRUTIDE is a cutting-edge, investigational triple hormone receptor agonist developed to address obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Unlike previous incretin-based therapies, it targets three critical pathways in metabolic regulation:
- GLP-1 receptor: Enhances insulin secretion, reduces appetite, and slows gastric emptying.
- GIP receptor: Supports insulin release and may improve fat metabolism.
- Glucagon receptor: Boosts energy expenditure and promotes fat breakdown through thermogenesis.
This triagonist mechanism offers superior metabolic impact compared to GLP-1-only or dual agonists like semaglutide and tirzepatide. Clinical studies have shown impressive weight loss and improvement in liver fat content and glycemic control. |
| Administration |
Intramuscular (IM) or Subcutaneous (SC) injection. |
| Storage |
- Before reconstitution: Store at room temperature, away from direct heat and sunlight.
- After reconstitution: Store refrigerated between 2–8°C. Use within the recommended time post-reconstitution.
|
| Dosage |
Initial dosing typically starts at 2mg once weekly, with gradual escalation to 4mg, 8mg, or up to 12mg weekly based on patient tolerance and clinical objectives. Dose increments are generally recommended every 4 weeks.
This titration strategy is intended to minimize gastrointestinal side effects and improve patient compliance. All dose adjustments should be conducted under medical supervision. |
| Contraindications |
Do not use BETA TRUTIDE if:
- You or any family member has a history of medullary thyroid carcinoma (MTC)
- You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- You are allergic to retatrutide or any excipient in the formulation
|
| Special Precautions |
- Thyroid Tumors: Preclinical studies showed C-cell tumors in animals. Risk to humans is uncertain; use is contraindicated in high-risk individuals.
- Pancreatitis: Discontinue use if persistent or severe abdominal pain occurs.
- Renal Impairment: Caution advised. Gastrointestinal side effects may lead to dehydration and worsening renal function.
- Diabetic Retinopathy: Rapid improvements in glycemia may worsen existing retinopathy—monitor affected patients closely.
- Pregnancy & Lactation: Safety has not been established. Avoid use unless specifically directed by a healthcare provider.
|
| Adverse Drug Reactions |
- Common: Nausea, diarrhea, vomiting, constipation, appetite suppression, abdominal discomfort.
- Rare: Injection site irritation, hypersensitivity, dehydration, gallbladder dysfunction, thyroid anomalies, visual disturbances.
|
| Drug Interactions |
Caution is required when used with:
- Insulin or sulfonylureas – Risk of hypoglycemia
- Oral medications – Delayed gastric emptying may impair absorption
- It is essential to review the patient’s full medication list and monitor closely when starting BETA TRUTIDE.
|
| Disclaimer |
Images shown are for representational purposes only and may not reflect the actual product received. Packaging may change without prior notice. |
Reviews
There are no reviews yet.